The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive people, might be able to prevent HIV transmission, according to a presentation at the International Clinical Pharmacology Workshop in Amsterdam.
Though Viread (tenofovir) and Truvada (tenofovir plus emtricitabine) are the leading antiretroviral (ARV) treatments being tested for use in HIV-negative people to prevent HIV infection, other ARVs are being considered for pre-exposure prophylaxis (PrEP). Researchers have also begun studying whether treating HIV-positive people, regardless of their CD4 count or medical need for ARV therapy, might help them reduce the risk of transmitting HIV to their HIV-negative partners.
Read the rest.
